Cancer immunotherapy company Liminatus Pharma has agreed to pay out shares worth $320 million to buy CAR-T biotech InnocsAI. | Cancer immunotherapy company Liminatus Pharma has agreed to pay out ...

Scientists at the UCLA Health Jonsson Comprehensive Cancer Center have developed a new cytokine-armored CAR-T cell therapy ...

It’s been more than four years since Novartis shook up the CAR-T space with its T-Charge platform. But that’s a lifetime in ...

New approach recruits the body’s immune system to attack glioblastoma while reducing treatment-related toxicity.

Personalized medicine is already a reality in clinical practice, and CAR-T cell therapy is one of its most promising tools. This innovative approach, which involves genetically modifying the cells of ...

Researchers were perplexed when the Food and Drug Administration announced it was investigating whether CAR-T therapy, one of the most effective treatments for blood cancers, could cause lymphoma.

Patty said that for caregivers, it’s essential to lean on the care team for information specific to the procedure, medication ...

Please provide your email address to receive an email when new articles are posted on . After first generating excitement in late 2022, this year was a bonanza for news about chimeric antigen receptor ...

Presentation will showcase recent data from multiple clinical studies evaluating dual-targeting CD19/BCMA CAR-T therapy candidate ...

Targeting KMA seeks to spare normal immunoglobulin-producing plasma cells, differentiating from BCMA-directed CAR T ...

The fresh funds will support the biotech's pipeline of RNA-based CAR-T cell therapies for cancer and autoimmune conditions.

The immune system is made up of different types of cells, which have different roles in protecting the body from infection. One type of immune cell called a B cell creates antibodies that attack ...